• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Pemphigus Vulgaris Companies

    ID: MRFR/Pharma/5405-CR
    128 Pages
    Rahul Gotadki
    July 2019

    Pemphigus vulgaris is a rare autoimmune blistering skin disease that requires comprehensive management and treatment. Companies associated with pemphigus vulgaris may provide pharmaceuticals, diagnostic tools, research, and support services.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Pemphigus Vulgaris Market Research Report - Global Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Pemphigus Vulgaris Market

    Pemphigus Vulgaris Key CompaniesDisclaimer: List of key companies in no particular orderLatest Pemphigus vulgaris Companies Update



    • Jan 2023: The directSTIM Deep Brain Stimulation (DBS) system from Switzerland-based Aleva Neurotherapeutics has been granted the CE mark. The precise current steering towards the intended structural location made possible by the DBS system technology increases the efficacy of DBS and lowers the possibility of adverse effects. The only technological company to obtain a CE mark for a DBS system is reportedly Aleva Neurotherapeutics. Through a post-market clinical follow-up study, it will start direct sales in a few European neurological clinics. Their Deep Brain Stimulation System combines the best directional electrode technology with a user-friendly patient programming interface to help functional neurosurgery teams treat patients more effectively.




    • June 2023: According to the business, Argenx SE's under-the-skin injection has been licensed by the US Food and Drug Administration to treat generalized myasthenia gravis, a genetic illness that weakens muscles. The medication, known as Vyvgart Hytrulo, is anticipated to go on sale in the United States the following month and has a list price of $15,773. The drug's intravenous version, Vyvgart, was approved by the FDA in 2021. However, the manufacturer anticipates that an under-the-skin version will provide more convenient administration than an intravenous infusion. Over $400 million was made in sales globally by Vyvgart last year. The chronic neuromuscular condition known as generalised myasthenia gravis (gMG) is brought on by an aberrant immune response that weakens the muscles in various body areas. The drug was approved based on late-stage research that demonstrated Vyvgart Hytrulo was non-inferior to Vyvgart in lowering the levels of a specific type of antibody while managing the autoimmune disease.


    List of Pemphigus vulgaris Key companies in the market

    • Almirall, SA

    • Argenx SE

    • Biogen Inc.

    • F. Hoffmann-La Roche

    • Syntimmune

    • Pfizer Inc.

    • Novartis AG

    • Sanofi

    • Janssen Global Services, LLC

    • Principia Biopharma